John M.  Capek net worth and biography

John Capek Biography and Net Worth

John Capek, Ph.D., is Executive Vice President, Ventures. Dr. Capek was appointed to his current position in June 2015. In this role, he leads Abbott’s venture investment organization as well as new ventures, including Abbott Electrophysiology. Previously, he had served as Executive Vice President, Medical Devices, and Senior Vice President, Abbott Vascular, heading up Abbott's global vascular business.

Before joining Abbott, Dr. Capek served in various management roles at Guidant Corporation, including president, Guidant Vascular Intervention and vice president and general manager of Bioabsorbable Vascular Solutions. He also served as vice president and general manager of Guidant Germany and vice president, marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Dr. Capek was manager of New Product Technology at Eli Lilly & Company.

He has a bachelor's degree in biomedical engineering, a master's degree in biomedical engineering, a master's degree in electrical engineering, a Ph.D. in biomedical engineering and a master's degree in business administration from Rensselaer Polytechnic Institute.

What is John M. Capek's net worth?

The estimated net worth of John M. Capek is at least $37.99 million as of June 20th, 2019. Mr. Capek owns 355,435 shares of Abbott Laboratories stock worth more than $37,992,447 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Capek may own. Learn More about John M. Capek's net worth.

How do I contact John M. Capek?

The corporate mailing address for Mr. Capek and other Abbott Laboratories executives is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. Abbott Laboratories can also be reached via phone at (224) 667-6100. Learn More on John M. Capek's contact information.

Has John M. Capek been buying or selling shares of Abbott Laboratories?

John M. Capek has not been actively trading shares of Abbott Laboratories over the course of the past ninety days. Most recently, John M. Capek sold 46,900 shares of the business's stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $85.00, for a transaction totalling $3,986,500.00. Following the completion of the sale, the executive vice president now directly owns 355,435 shares of the company's stock, valued at $30,211,975. Learn More on John M. Capek's trading history.

Who are Abbott Laboratories' active insiders?

Abbott Laboratories' insider roster includes Hubert Allen (Insider), Roxanne Austin (Director), Roger Bird (SVP), Brian Blaser (Insider), Philip Boudreau (VP), Sharon Bracken (Insider), John Capek (EVP), Jaime Contreras (SVP), Michael Dale (SVP), Lisa Earnhardt (EVP), Robert Ford (Chairman), Robert Ford (CEO), Robert Funck (CFO), Stephen Fussell (EVP), John Ginascol (EVP), Sammy Karam (SVP), Michelle Kumbier (Director), Andrew Lane (EVP), Joseph Manning (SVP), John Mccoy Jr. (VP), Nancy Mckinstry (Director), Mary Moreland (EVP), Louis Morrone (SVP), Phebe Novakovic (Director), Michael Pederson (SVP), Daniel Salvadori (EVP), Christopher Scoggins (SVP), Daniel Starks (Director), Julie Tyler (SVP), Andrea Wainer (EVP), Jared Watkin (SVP), Miles White (Chairman), Randel Woodgrift (SVP), and Brian Yoor (CFO). Learn More on Abbott Laboratories' active insiders.

Are insiders buying or selling shares of Abbott Laboratories?

During the last year, insiders at the healthcare product maker sold shares 10 times. They sold a total of 240,061 shares worth more than $26,014,576.06. The most recent insider tranaction occured on March, 1st when EVP Daniel Gesua Sive Salvadori sold 963 shares worth more than $114,115.50. Insiders at Abbott Laboratories own 1.1% of the company. Learn More about insider trades at Abbott Laboratories.

Information on this page was last updated on 3/1/2024.

John M. Capek Insider Trading History at Abbott Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/20/2019Sell46,900$85.00$3,986,500.00355,435View SEC Filing Icon  
2/4/2015Sell34,292$45.66$1,565,772.72View SEC Filing Icon  
See Full Table

John M. Capek Buying and Selling Activity at Abbott Laboratories

This chart shows John M Capek's buying and selling at Abbott Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abbott Laboratories Company Overview

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $106.89
Low: $106.15
High: $107.46

50 Day Range

MA: $113.77
Low: $105.27
High: $120.98

2 Week Range

Now: $106.89
Low: $89.67
High: $121.64

Volume

3,111,313 shs

Average Volume

5,687,034 shs

Market Capitalization

$185.47 billion

P/E Ratio

33.30

Dividend Yield

2.04%

Beta

0.74